FG001 is proven safe in patients undergoing surgery for cancer - a significant milestone for FluoGuide to further advance clinical development in aggressive brain cancer and in a prevalent indication
Copenhagen, Denmark, 8 October 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 has been concluded to be safe and well tolerated by the dose escalation committee monitoring the ongoing phase I/II clinical trial. Safety data from 27 patients with aggressive brain cancer (including the just-completed seventh cohort) have been reviewed, and FG001 has proven to have a very satisfactory safety and tolerability profile in all 27 patients. In the completed seventh cohort, light was detected in all three patientsIt is an important milestone for FluoGuide to now